^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

JIN-A02

i
Other names: JIN-A02
Company:
J Ints Bio
Drug class:
EGFR inhibitor
Related drugs:
over1year
A Phase 1, 2 Study to Evaluate the Safety and Anti-tumor Activity of JIN-A02 in Patients with EGFR Mutant Advanced NSCLC (IASLC-WCLC 2023)
JIN-A02, a 4th generation EGFR TKI, selectively and reversibly binds to EGFR mutations, including C797S mutation that causes resistance to Osimertinib. Primary end points include dose limiting toxicity and AE/SAE for part A, RP2D for part B, and objective response rate for part C. Part A of JIN-A02 study has begun site activation in January 2023 in US, approved in Korea and is awaiting regulatory approval in Thailand. Clinical trial information: NCT05394831
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR C797S • EGFR positive
|
Tagrisso (osimertinib) • JIN-A02
almost2years
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC (clinicaltrials.gov)
P1/2, N=150, Recruiting, J Ints Bio | Not yet recruiting --> Recruiting | N=95 --> 150 | Trial completion date: Dec 2024 --> Nov 2025 | Trial primary completion date: Dec 2023 --> Jul 2024
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR C797S • EGFR positive
|
JIN-A02
over2years
New P1/2 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
JIN-A02